1132 GMT - Sanofi is among the most mentioned companies across news items over the past six hours, according to Factiva data. The French pharma major reported that it stopped clinical development of its once-promising breast-cancer treatment amcenestrant after an independent monitoring committee said that the drug didn't meet requirements to continue its study. Sanofi is discontinuing a trial for the study of amcenestrant in advanced or metastatic breast cancer, as well as other studies for early-stage disease, it said. Sanofi shares fell on the news and at 1126 GMT traded 3.7% down at EUR83.36. Dow Jones & Co. owns Factiva. ( cecilia.butini@wsj.com)

(END) Dow Jones Newswires

August 17, 2022 07:47 ET (11:47 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Sanofi Charts.